These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12473751)

  • 21. Cooperative control of striated muscle mass and metabolism by MuRF1 and MuRF2.
    Witt CC; Witt SH; Lerche S; Labeit D; Back W; Labeit S
    EMBO J; 2008 Jan; 27(2):350-60. PubMed ID: 18157088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic myopathies.
    Hirano M; DiMauro S
    Adv Neurol; 2002; 88():217-34. PubMed ID: 11908228
    [No Abstract]   [Full Text] [Related]  

  • 23. Molecular mechanisms responsible for alcohol-induced myopathy in skeletal muscle and heart.
    Lang CH; Frost RA; Summer AD; Vary TC
    Int J Biochem Cell Biol; 2005 Oct; 37(10):2180-95. PubMed ID: 15982919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A mutation in myotilin causes spheroid body myopathy.
    Foroud T; Pankratz N; Batchman AP; Pauciulo MW; Vidal R; Miravalle L; Goebel HH; Cushman LJ; Azzarelli B; Horak H; Farlow M; Nichols WC
    Neurology; 2005 Dec; 65(12):1936-40. PubMed ID: 16380616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diversification of the muscle proteome through alternative splicing.
    Nakka K; Ghigna C; Gabellini D; Dilworth FJ
    Skelet Muscle; 2018 Mar; 8(1):8. PubMed ID: 29510724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consequences of mutations within the C terminus of the FHL1 gene.
    Schoser B; Goebel HH; Janisch I; Quasthoff S; Rother J; Bergmann M; Müller-Felber W; Windpassinger C
    Neurology; 2009 Aug; 73(7):543-51. PubMed ID: 19687455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and cellular defects of skeletal muscle in an animal model of acute quadriplegic myopathy.
    Mozaffar T; Haddad F; Zeng M; Zhang LY; Adams GR; Baldwin KM
    Muscle Nerve; 2007 Jan; 35(1):55-65. PubMed ID: 16967495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of the dysferlin skeletal muscle promoter.
    Foxton RM; Laval SH; Bushby KM
    Eur J Hum Genet; 2004 Feb; 12(2):127-31. PubMed ID: 14560310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic approaches for the sarcomeric protein diseases.
    Nowak KJ
    Adv Exp Med Biol; 2008; 642():207-23. PubMed ID: 19181103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 133rd ENMC International Workshop on Congenital Muscular Dystrophy (IXth International CMD Workshop) 21-23 January 2005, Naarden, The Netherlands.
    Muntoni F; Voit T
    Neuromuscul Disord; 2005 Nov; 15(11):794-801. PubMed ID: 16199159
    [No Abstract]   [Full Text] [Related]  

  • 31. Translational control of muscle mass.
    Dupont-Versteegden EE; McCarthy JJ
    J Appl Physiol (1985); 2019 Aug; 127(2):579-580. PubMed ID: 31446832
    [No Abstract]   [Full Text] [Related]  

  • 32. Congenital myopathies.
    Laing NG
    Curr Opin Neurol; 2007 Oct; 20(5):583-9. PubMed ID: 17885449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations.
    Huizing M; Rakocevic G; Sparks SE; Mamali I; Shatunov A; Goldfarb L; Krasnewich D; Gahl WA; Dalakas MC
    Mol Genet Metab; 2004 Mar; 81(3):196-202. PubMed ID: 14972325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exome Sequencing Identified a Splice Site Mutation in FHL1 that Causes Uruguay Syndrome, an X-Linked Disorder With Skeletal Muscle Hypertrophy and Premature Cardiac Death.
    Xue Y; Schoser B; Rao AR; Quadrelli R; Vaglio A; Rupp V; Beichler C; Nelson SF; Schapacher-Tilp G; Windpassinger C; Wilcox WR
    Circ Cardiovasc Genet; 2016 Apr; 9(2):130-5. PubMed ID: 26933038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3rd Annual Dysferlin Conference 2-5 June 2009, Boston, Massachusetts, USA.
    Albrecht DE; Garg N; Rufibach LE; Williams BA; Monnier N; Hwang E; Mittal P
    Neuromuscul Disord; 2009 Dec; 19(12):867-73. PubMed ID: 19781937
    [No Abstract]   [Full Text] [Related]  

  • 36. A new phenotype of dysferlinopathy with congenital onset.
    Paradas C; González-Quereda L; De Luna N; Gallardo E; García-Consuegra I; Gómez H; Cabello A; Illa I; Gallano P
    Neuromuscul Disord; 2009 Jan; 19(1):21-5. PubMed ID: 19084402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unfolded protein response and aggresome formation in hereditary reducing-body myopathy.
    Liewluck T; Hayashi YK; Ohsawa M; Kurokawa R; Fujita M; Noguchi S; Nonaka I; Nishino I
    Muscle Nerve; 2007 Mar; 35(3):322-6. PubMed ID: 17099882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Congenital myopathies: diseases of the actin cytoskeleton.
    Clarkson E; Costa CF; Machesky LM
    J Pathol; 2004 Nov; 204(4):407-17. PubMed ID: 15495263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of the intermediate filament protein synemin in myofibrillar myopathies and other muscle diseases.
    Olivé M; Goldfarb L; Dagvadorj A; Sambuughin N; Paulin D; Li Z; Goudeau B; Vicart P; Ferrer I
    Acta Neuropathol; 2003 Jul; 106(1):1-7. PubMed ID: 12669240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tubular aggregates are from whole sarcoplasmic reticulum origin: alterations in calcium binding protein expression in mouse skeletal muscle during aging.
    Chevessier F; Marty I; Paturneau-Jouas M; Hantaï D; Verdière-Sahuqué M
    Neuromuscul Disord; 2004 Mar; 14(3):208-16. PubMed ID: 15036331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.